Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NYV6
UPID:
RRN3_HUMAN
Alternative names:
Transcription initiation factor IA
Alternative UPACC:
Q9NYV6; A2RTY9; B4E0J7; B4E3T2; Q3MHU9; Q6IPL4; Q9H4F0
Background:
RNA polymerase I-specific transcription initiation factor RRN3, also known as Transcription initiation factor IA, plays a pivotal role in the transcription initiation by RNA polymerase I. It is essential for the formation of a competent preinitiation complex (PIC) and dissociates from pol I following transcription initiation. Despite its crucial function, RRN3 cannot activate transcription in subsequent reactions, highlighting its unique, non-repetitive role in transcription initiation.
Therapeutic significance:
Understanding the role of RNA polymerase I-specific transcription initiation factor RRN3 could open doors to potential therapeutic strategies.